Richard Stone, MD: How do we treat the patient like this?
Eunice Wang, MD: In this instance, Id look at the overall presentation of the patient. AML [acute myeloid leukemia] therapy in the current era requires that we individualize the treatment regimen for the patient and disease. This woman has undergone intensive or definitive therapy for her breast cancer. Shes still functionally active, has an excellent performance status, and doesnt have any evidence of organ dysfunction, eg, liver, kidney, or heart. Her activity level is normal. Shes continuing to work full-time, chasing high school students around.
Id think about offering her an intensive chemotherapy approach, potentially followed by allogeneic stem cell transplant for curative intent. Because we know that in most patients with a secondary therapyrelated AML, the best outcomes are achieved by the performance of an allogeneic stem cell transplant as postconsolidation therapy. What are your thoughts on this?
Richard Stone, MD: I agree with everything you said. When I think about intensive chemotherapy, I think about whether the patient can tolerate it and whether it will benefit the patient. Because there are certain patients who can tolerate intensive chemotherapy, but Im not sure [they] would benefit from it. Its still an open question. In other words, patients with a TP53 mutation and complex karyotype may not benefit from intensive chemotherapy. They may not [have] better [results] with azacitidine and venetoclax, but at least theyre not going to be as sick.
Without any proof, I have a predilection to treat the patients [with high-risk disease] with less intensive chemotherapy, because it isnt likely to be worse and will likely be better tolerated. Thats unproven at the moment. For this patient, Id use an intensive approach because of her age, favorable mutational status, and good performance status. I have a similar view that she should get an intensive regimen. What do you think are the choices for an intensive regimen?
Eunice Wang, MD: This patient is over the age of 60, which makes it more straightforward. But based on her age and the diagnosis of a secondary therapyrelated AML, my preference would be to treat her with CPX-351, or liposomal cytarabine-daunorubicin. That offers her the best opportunity to be free of disease in 3 to 5 years.
There were the results of a phase 3 randomized clinical trial where patients aged 60 to 75 [years] with secondary AML were [randomly assigned] to receive up-front induction of chemotherapy with either CPX-351that liposomal formulation is dosed on days 1, 3, and 5[or] the standard continuous infusion [of] cytarabine and daunorubicin, our 7+3 gold standard. In that trial, patients could get 2 cycles of the CPX-351 induction or 7+3. They could get consolidation with a CPX-351 vs a 5+2. Eligible patients could then go on to subsequent transplant.
The 5-year results were published in 2021 and substantiate the early findings that led to FDA approval, where about 18% in the CPX-351 group and 8% in the 7+3 group were alive and disease-free at 5 years. Of the patients who had gotten CPX-351 followed by transplant, most impressively, 53% were alive. The overall survival for those patients who had gone to subsequent transplant from CPX-351 hadnt been reached yet. I was impressed with that because in the past, patients who got therapy-related AML rarely went into remission or long-term response. Very few of themless than 10% with standard therapy[survived for] 3 to 5 years. Based on those data, Id be offering CPX-351 to this patient.
The only question would beand I throw this back to youwhat if she were 59 [years old]? Would you treat her similarly? Because the trial was for patients aged 60 to 75 years. If she were 55 or 45 [years old], would you do the same thing? Or would you restrict your interpretation of that trial to the [patients aged] 60 to 75?
Richard Stone, MD: Thats a great question. The FDA believes you could extend the [use] of CPX-351 to younger folks because they approved it in an age-agnostic fashion, which was surprising because, as you pointed out, the data were only [from results of] patients aged 60 to 75 [years]. Its possible that a 7+3 regimen would have been better than CPX-351 for younger patients. They did a trial in all ages, [but] it didnt show better results. They did a trial with older adults, and it was only the ones who had secondary AML who seemed to benefit from CPX-351 compared with 7+3. Its a little unclear, but I believe its because CPX-351 seems to release ARA-C [cytosine arabinoside] and daunorubicin, a so-called favorable molar ratio, to kill the cells. Thats more theoretical, but its true. It also [remains] in the bone marrow a little longer, which accounts for its mild suppression. Maybe thats another reason why its a little better.
The answer to your question is that Id use it in a younger patient who had secondary AML. Curiously, in another post hoc analysis done by R. Coleman Lindsley, [MD, PhD], of the CPX-351 vs 7+3 trial that you mentioned, [patients] with TP53 mutations didnt benefit from CPX-351 compared with 7+3. Thats another situation where you throw up your hands. [These] were [patients aged] 60 to 75, but Id use it in the right patient under 60 [years of age]. In fact, theres an ongoing trial in Europe for patients regardless of their history of MDS [myelodysplastic syndrome] or prior treatment that will compare 7+3 with CPX-351. Maybe it will turn out to be a better induction regimen than 7+3 alone. We need to wait and see.
We talked about CPX-351 compared with azacitidine-venetoclax in the retrospective studies that were published at the American Society of Hematology meeting. CPX-351 is similar to 7+3 chemotherapy, but different in that its given episodically on days 1, 3, and 5. As you mentioned, its possible to give this [treatment] outpatient if the patient isnt ill, and we do that too. It saves hospitalization. Its also financially toxic to the inpatient service to pay for CPX-351, which is very expensive compared with 7+3. But you may save money by not admitting the patient for as many days. We bring them in on day 10 at the start of their expected nadir, because almost all of them will [have] some fever and neutropenia, and its easier to have them in the hospital when that happens than outpatient [service].
We find CPX-351 to be well tolerated in general, with no hair loss, minimal GI [gastrointestinal] toxicity, and as you mentioned, prolonged myelosuppression. Those are the main considerations with CPX-351. Its cardiotoxic. Its hard to know how it compares with standard daunorubicin, or even doxorubicin, for those who have secondary AML. [For] your patient, its important to consider the prior doxorubicin if they were treated for breast cancer or another cancer. We get echocardiograms frequently for our CPX-351 patients. Any other thoughts about that, Eunice?
Eunice Wang, MD: As you mentioned, there are a lot of things to recommend in terms of the toxicity profile. Our patients are excited about the fact that they dont lose their hair and [wont] be inpatient for 40, 50, or 60 days. In general, there are still the complications from infection, but the ability to do part of the regimen outpatient and then do all the regimen outpatient in the consolidation setting while waiting for possible transplant improves quality of life. [It] has been demonstrated in other studies that, as compared with 7+3 and standard consolidation, patients have almost 50% improved quality-of-life scores on various questionnaires when asked about the comparison between the 2. Thats an important thing to keep in mind as were tailoring therapy for the patient and the disease.
Transcript edited for clarity.
Continued here:
CPX-351 in Treatment of AML and Clinical Considerations - OncLive
- Unable to find a partner for stem cell therapy, Gamida accepts sale to investment firm to survive - Fierce Biotech - March 28th, 2024
- Putting Stem Cell-Based Therapies in Context - National Institutes of ... - January 31st, 2024
- Global Stem Cell Therapy Industry Outlook to 2028, Driven by Therapeutic Innovations and Clinical Advancements ... - Yahoo Finance - January 31st, 2024
- Stem Cell Transplant and CAR T-cell Therapy: The Patient and Care Partner Experience | BMT Infonet - BMT Infonet | - January 31st, 2024
- New study on promising stem cell-based therapy for Crohn's disease - Medical Xpress - January 31st, 2024
- The Trouble With Stem Cell Therapy - Consumer Reports - December 20th, 2023
- Stem Cell Therapy Boosts Quality of Life for People With Advanced Heart Failure - MedicineNet - December 20th, 2023
- The stem cell therapy project Blue4Therapy brought to a highly successful close - Marketscreener.com - April 7th, 2023
- Stem Cell Therapy for Spinal Cord Injury - PubMed - December 27th, 2022
- How much does stem cell therapy cost in 2022? - The Niche - December 18th, 2022
- How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM - December 18th, 2022
- Ethical issues in stem cell research and therapy - December 10th, 2022
- EdiGene to Present Preliminary Safety and Efficacy Results of an Investigator Initiated Trial for ET-01, its Investigational Gene Editing... - November 6th, 2022
- Global Stem Cell Umbilical Cord Blood (UCB) Market Report 2022-2026: Increased Federal Investment in Stem Cell Therapy, and the Advent of Cord Blood... - October 21st, 2022
- Global Cell Culture Protein Surface Coating Market to Grow at a CAGR of 13.82% During 2022-2031; Market to Expand on the Back of the Technological... - October 21st, 2022
- Stem Cell Therapy for Knees - thriveMD Denver & Vail, CO - October 13th, 2022
- Stem cell therapy and autism | Raising Children Network - October 13th, 2022
- Cellectis Presents Data on Two TALEN-based Gene Therapy Preclinical Programs for Patients with ... - The Bakersfield Californian - October 13th, 2022
- Global Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027 - Yahoo Finance - October 13th, 2022
- 2023 to be highly lucrative for drug developers across therapeutic areas: Report - BSI bureau - October 13th, 2022
- Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and ... - October 4th, 2022
- Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the... - October 4th, 2022
- Innovative Imaging Techniques to Accelerate the Discovery of New... - Healthcare Tech Outlook - October 4th, 2022
- Celtic-mad dad left unable to talk after horror attack as family fundraise for stem cell therapy... - The Scottish Sun - September 25th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - Benzinga - September 16th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - GlobeNewswire - September 16th, 2022
- Radical lupus treatment uses CAR T-cell therapy developed for cancer - New Scientist - September 16th, 2022
- Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with... - September 16th, 2022
- T-Cell Redirection Therapy Shows Promise As Salvage Therapy in R/R Multiple Myeloma - Targeted Oncology - September 16th, 2022
- Orca Bio expands manufacturing capabilities to take cell therapies through to commercialization - BioPharma-Reporter.com - September 16th, 2022
- BioRestorative Therapies : BRTX Presentation September 2022 - Marketscreener.com - September 16th, 2022
- Advanced cellular therapy brings hope to KSA cancer patients - Omnia Health Insights - September 16th, 2022
- IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400 - BioSpace - September 16th, 2022
- The five hottest private biotech companies in India - Labiotech.eu - September 16th, 2022
- Be The Match and William G. Pomeroy Foundation Announce $500k Gift and Matching Campaign - PR Newswire - September 16th, 2022
- California man appears to be another person cured of HIV after a stem cell transplant - aidsmap - August 5th, 2022
- Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies - PR... - August 5th, 2022
- Induced Pluripotent Stem Cell (iPSC) Global Market to Reach $3.57 Billion by 2026 - Benzinga - August 5th, 2022
- The Role of Cell Banking Outsourcing Market Industry Growth, Competitors Analysis, New Technology, Trends and Forecast 2020 2030 - Digital Journal - August 5th, 2022
- World to Witness Surging Use of Neurostimulation & Neuromodulation Devices for Nerve Repair and Regeneration, Predicts Fact.MR - GlobeNewswire - August 5th, 2022
- Dr. Owhofasa Agbedia Honored With The 2022 ASH-CIBMTR-ASTCT Career Development Award - Business Wire - August 5th, 2022
- Novel Drug-Chemotherapy Combo After Stem Cell Transplant Associated With 'Favorable Survival Outcomes' in Group of Rare Blood Cancers - Curetoday.com - July 27th, 2022
- Broadening access to cancer fighting therapy led by UH researcher | University of Hawaii System News - University of Hawaii - July 27th, 2022
- Petition calling for 'life-changing' MS treatment funding handed to Parliament - Stuff - July 27th, 2022
- How effective is stem cell therapy for liver cirrhosis? - Times of India - July 27th, 2022
- Kite's CAR T-cell Therapy Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) - Gilead Sciences - July 27th, 2022
- S'porean doctor, a sought-after top expert in cell therapy, appointed to WHO expert panel - The Straits Times - July 27th, 2022
- Top 10 Advances in Large B-Cell Lymphomas in the Past 10 Years - Targeted Oncology - July 27th, 2022
- Stem Cell Therapy Market Emerging Trends to Make Driving Growth on Key Players Status - Taiwan News - July 19th, 2022
- PROMISING STEM CELL THERAPY IN THE MANAGEMENT OF HIV & AIDS | BTT - Dove Medical Press - July 11th, 2022
- Global Stem Cell Manufacturing Market Value Projected To Reach USD 21.71 Billion By 2029, Registering A CAGR Of 9.1% - Digital Journal - July 11th, 2022
- Diabetic foot treatment: Here's all you need to know about stem cell therapy - Hindustan Times - July 11th, 2022
- Every 5 minutes someone in India is diagnosed with blood cancer or a blood disorder: Patrick Paul, CEO, DKMS BMST Foundation India - The Financial... - July 11th, 2022
- Growing Prevalence & Recurrence Of Rheumatoid Arthritis Is Expected To Growth Of The Rheumatoid Arthritis Stem Cell Therapy Market Designer Women... - July 11th, 2022
- New sickle cell disease gene therapies depend on getting the right mouse - EurekAlert - July 11th, 2022
- Market Share, Supply, Analysis and Forecast of Human Insulin Drugs and Delivery Devices to 2026 Designer Women - Designer Women - July 3rd, 2022
- Gamida Cell Submits Biologics License Application for Omidubicel to the FDA - Pharmacy Times - June 22nd, 2022
- Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -... - June 22nd, 2022
- Stem Cell Therapy in Jacksonville at Pangenics Regenerative Center - June 13th, 2022
- Stem-Cell Based Therapy Shows Promise in Treating High-Risk Type 1 Diabetes - Newswise - June 13th, 2022
- What Is Myelofibrosis? Symptoms, Causes, Diagnosis, Treatment, and Prevention - Everyday Health - June 13th, 2022
- European Commission Approves Mosunetuzumab for Patients with R/R Follicular Lymphoma - Targeted Oncology - June 13th, 2022
- Global Human Embryonic Stem Cell Market To Be Driven By The Rapid Technological Advancements In The Forecast Period Of 2022-2027 The Greater... - June 4th, 2022
- Pancreatic Cancer Therapy Experiment Saves Woman; Is It A Breakthrough? - Kaiser Health News - June 4th, 2022
- Dedication, Achievement and Grace in Cancer Care - Curetoday.com - June 4th, 2022
- Nerve Repair and Regeneration Market worth $11.6 billion by 2027 - Exclusive Report by MarketsandMarkets - Yahoo Finance - June 4th, 2022
- Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis - DocWire News - June 4th, 2022
- High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study - AJMC.com Managed Markets Network - June 4th, 2022
- JASPER THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - May 15th, 2022
- Cell Culture Market to Gain US$ 27.6 Bn by 2031, Burgeoning Demand for Biosimilars and Biologic Therapeutics Fueling Market Growth - BioSpace - May 15th, 2022
- Pilot Study Shows Promising Results With CPX-351 in Relapsed/Refractory ALL - OncLive - May 15th, 2022
- Primary Cell Culture Market Mechanical Separation Segment Is Expected To Witness A Lucrative CAGR Of 11.7 - Benzinga - May 15th, 2022
- Vale man with MS needs 50,000 for treatment in Mexico - Evesham Journal - May 2nd, 2022
- Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO... - May 2nd, 2022
- Long-Term Axi-Cel Data 'May Be Suggestive of a Cure' in Patients With Large B-Cell Lymphoma - Curetoday.com - May 2nd, 2022
- Billy Connolly donates painting to Glasgow woman diagnosed with cancer five times - Glasgow Times - May 2nd, 2022
- The Progress Made in Stem Cell Therapy, Regenerative Medicine: Peter J. McAllister, MD, FAAN - Neurology Live - April 19th, 2022
- AACR: Resistance Mechanisms to CAR-T Cell Therapy ID'd in ALL - HealthDay News - April 19th, 2022
- 2022-04-18 | NDAQ:BRTX | Press Release | BioRestorative Therapies Inc - Stockhouse - April 19th, 2022
- First Patient With Lymphoma Receives Novel Cell Therapy in Large-Scale Trial - Curetoday.com - April 6th, 2022